

CLEARBRIDGE HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 201001436C)

PROPOSED DISPOSAL OF SHARES IN BIOMEDICS LABORATORY PTE. LTD.
– SGX QUERIES

Unless otherwise defined herein or the context otherwise requires, all capitalized terms used in this announcement shall bear the same meanings ascribed to them in the Company's announcement dated 27 March 2020 in relation to the Proposed Disposal ("**Announcement**").

Further to the Announcement, the Board of Clearbridge Health Limited (the "**Company**" or "**Clearbridge**") wishes to provide the following additional information in response to the queries raised by the SGX-ST.

QUESTION 1

Given that Yee Pinh Jeremy and Chen Johnson are directors of both Biolidics Limited (Purchaser) and Clearbridge Health Limited (Seller), did they partake in the decision-making process in relation to Clearbridge's decision to sell Biomedics to Biolidics?

Both Yee Pinh Jeremy and Chen Johnson did not participate in the decision-making process of the proposed disposal of Biomedics Laboratory Pte Ltd. The Proposed Disposal was deliberated on and decided by the remaining directors of Clearbridge who do not have any interest in the Proposed Disposal and are independent.

QUESTION 2

Who solicited/initiated the sale of Biomedics to Biolidics?

The Proposal Disposal was initiated by Biolidics Limited ("**Biolidics**"). We understand that Biolidics is planning to set up a clinical laboratory to provide services which are required to be carried out in a CAP-accredited laboratory. However, having taken into account the prevailing costs of equipment and the salaries of key employees such as pathologists, the board of directors of Biolidics believes that it will entail more time and financial resources for it to set up a new clinical laboratory. Further, there is also no certainty that it will attain the CAP accreditation. As such, Biolidics had approached SAM Laboratory Pte Ltd to acquire its clinical laboratory, the only CAP-accredited laboratory for the detection of circulating tumour cells under the anatomical pathology discipline in Asia.

QUESTION 3

The remaining board members of both Biolidics (4 Independent Directors) and Clearbridge (4 Independent Directors) are independent. Apart from Yee Pinh Jeremy and Chen Johnson, whom in Clearbridge led the disposal of Biomedics?

The Proposed Disposal was led by Clearbridge's executive officers, namely, Liau Yen San, Jonathan (Chief Commercial Officer) and Simon Hoo Kia Wei (Chief Business Officer).

BY ORDER OF THE BOARD

Andrew John Lord
Lead Independent Director

3 April 2020

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*